DA32 Life Science Tech Acquisition Corp. (DALS) Research

Currently, DA32 Life Science Tech Acquisition Corp. does not engage in substantial operational activities. Its core objective is to finalize a business combination, which may involve a merger, an exchange of capital stock, an acquisition of assets or stock, or a corporate reorganization with other companies. The firm intends to pinpoint promising candidates for these combinations within the biotechnology and life science infrastructure sectors. Established in 2021, the company is based in New York, New York.

Market snapshot

Symbol
DALS
Price
$10.30
Day change
-0.19%
Market cap
$264.2M
52-week range
9.68-11.22
Sector
Financial Services
Industry
Shell Companies

Peer companies

  • Corazon Capital V838 Monoceros Corp (CRZN)
  • Ignyte Acquisition Corp. (IGNY)
  • Nauticus Robotics, Inc. (KITT)
  • Panacea Acquisition Corp. II (PANA)
  • CC Neuberger Principal Holdings III (PRPC)
  • Roadzen, Inc. (RDZN)
  • SILVERspac Inc. (SLVRU)
  • TenX Keane Acquisition Ordinary Share (TENK)

Recent insider activity

  • CRANDELL KEITH — J-Other (1600000 shares) on 2023-07-28
  • ARCH Venture Fund XI, L.P. — J-Other (1600000 shares) on 2023-07-28
  • DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) — J-Other (1600000 shares) on 2023-07-28
  • Section 32 Fund 3, LP — D-Return (701250 shares) on 2021-08-05
  • Section 32 Fund 3, LP — D-Return (30000 shares) on 2021-08-05

Open DA32 Life Science Tech Acquisition Corp. (DALS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.